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Abstract: Magnesium gluconate is a potent antioxidant used for the prevention and treatment of hypomagnesia. The 
current research was aimed to investigate the impact of The Trivedi Effect® - Energy of Consciousness Healing Treatment 
(Biofield Energy Healing Treatment) on magnesium gluconate for the change in the physicochemical, structural, thermal and 
behavioral properties using PXRD, PSD, FT-IR, UV-vis spectroscopy, TGA, and DSC analysis. Magnesium gluconate was 
divided into two parts – one part was control, while another part was treated with The Trivedi Effect® - Energy of 
Consciousness Healing Treatment (Biofield Energy Healing Treatment) remotely by twenty renowned Biofield Energy 
Healers and defined as The Trivedi Effect® treated sample. The PXRD analysis exhibited that the crystallite size of the 
treated sample was remarkably changed from range -37.52% to 180.14% compared with the control sample. The average 
crystallite size was reduced in the treated sample by 0.11% compared with the control sample. PSD analysis revealed that the 
particle sizes in the treated sample at d10 and d50 values were significantly decreased by 11.36% and 8.25%, respectively, 
while the particle size at d90 was increased in the treated sample by 2.43% compared with the control sample. The treated 
sample’s surface area was significantly increased by 9.54% compared with the control sample. The FT-IR and UV-vis 
analysis showed that the structure of the magnesium gluconate remained the same in both the treated and control samples. 
The TGA analysis revealed the four steps thermal degradation of the both samples and the total weight loss of the treated 
sample was reduced by 2.32% compared with the control sample. This result indicated that the thermal stability of the treated 
sample was improved compared with the control sample. The DSC analysis revealed that the melting temperature of the 
treated sample (171.05°C) was decreased by 0.17% compared with the control sample (171.34°C). The latent heat of fusion 
was decreased by 1.16% in the treated sample compared with the control sample. The current study infers that The Trivedi 
Effect® - Energy of Consciousness Healing Treatment (Biofield Energy Healing Treatment) might lead to a new polymorphic 
form of magnesium gluconate, which would be more soluble, bioavailable, and thermally stable compared with the untreated 
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compound. Hence, The Trivedi Effect® Treated magnesium gluconate would be very useful to design better nutraceutical 
and/or pharmaceutical formulations that might offer better therapeutic responses against inflammatory diseases, 
immunological disorders, stress, aging and other chronic infections. 
Keywords: Biofield Energy Healing Treatment, Consciousness Energy Healing Treatment, The Trivedi Effect®,  
Magnesium Gluconate, PXRD, Particle Size, Surface Area, TGA, DSC 
 
1. Introduction 
Magnesium ion (Mg2+) is a major intracellular ion and 
plays an important role in the regulation of tRNA and rRNA 
structures. This ion is also a crucial cofactor for many RNA 
and DNA processing enzymes as well as for those enzymes 
using AMP, ADP, or ATP as substrates [1-3]. Hence, 
magnesium ion is an essential mineral element in human and 
animal nutrition. It is also used as a metallotherapeutic agent 
to treat various diseases such as asthma, arrhythmias, acute 
myocardial infarction, gestational hypertension, preeclampsia 
and eclampsia [1-7]. Perioperative magnesium 
supplementation is found to be very useful in the management 
of postoperative pain by inhibiting postoperative 
hypomagnesia as well as reducing the incidence of 
postoperative shivering [8, 9]. Gluconic acid is a minor 
organic acid formed from glucose through a simple 
dehydrogenation reaction catalyzed by glucose oxidase. 
Gluconic acid and its derivatives are commonly used in the 
food and pharmaceutical industry [10]. Magnesium gluconate 
(MgC12H22O14) is the magnesium salt of gluconic acid. It is 
used by itself or in combination with one or more 
antioxidants for the prevention and treatment of diabetes 
mellitus, allergies, septic shock, inflammatory diseases, 
immunological disorders, and other chronic infections [11, 
12]. It can be used intravenously in the treatment of 
ischemia/reperfusion injury due to oxidative stress in order to 
block free radical flow [13]. This organometallic salt can be 
used in a skin-tightening cosmetic composition [14]. It is also 
used as an oral tocolytic agent in women, whose labor is 
arrested initially with intravenous therapy by acting on non-
selective β-receptor [15]. The scientific literature reports that 
magnesium gluconate is a more powerful antioxidant than 
other magnesium salts [11]. Moreover, magnesium gluconate 
is a physiologically acceptable salt among from the other salt 
forms [12]. The bioavailability of magnesium in humans is 
found low due to the difficulties in the absorption through the 
narrow channels in the biological membranes for its higher 
steric constraints to transporters and incapability of its 
hydration shell [16, 17]. Magnesium gluconate is 
physiologically acceptable salt and has the highest 
bioavailability among the magnesium salts such as chloride, 
sulfate, citrate, lactate, aspartate, etc. [12, 18]. In this point of 
view, a novel proprietary herbomineral formulation was 
designed as a nutraceutical supplement, which can be used for 
the prevention and treatment of various human disorders. 
Magnesium gluconate is one of the components in this novel 
proprietary herbomineral formulation as the source of 
magnesium. 
Since ancient times, many different cultures, religions and 
systems of belief have recognized a living force that 
preserves and inhabits every living organism. This force is the 
source of ‘life’ and has been called various names, such as 
prana by the Hindus, qi or chi by the Chinese, and ki by the 
Japanese. This is believed to co-relate with the soul, spirit and 
mind. This hypothetical vital force has been scientifically 
evaluated and is now considered the Bioenergetics Field. The 
Biofield Energy is a dynamic electromagnetic field 
surrounding the human body, resulting from the continuous 
emission of low-level light, heat, and acoustical energy from 
the body. Biofield Energy is infinite, paradimensional and can 
freely flow between the human and environment [19, 20]. So, 
a human has the ability to harness energy from the ionosphere 
of the earth, the “universal energy field”, and transmit it to 
any living organism (s) or nonliving object (s) around the 
globe. The object or recipient always receives the energy and 
responds in a useful way. This process is known as The 
Trivedi Effect® - Biofield Energy Healing Treatment [21]. 
Biofield (Putative Energy Field) based Energy Therapies are 
used worldwide to promote health and healing. The National 
Center of Complementary and Integrative Health (NCCIH) 
has recognized and accepted Biofield Energy Healing as a 
Complementary and Alternative Medicine (CAM) health care 
approach in addition to other therapies, medicines and 
practices such as natural products, deep breathing, yoga, Tai 
Chi, Qi Gong, chiropractic/osteopathic manipulation, 
meditation, massage, special diets, homeopathy, progressive 
relaxation, guided imagery, acupressure, acupuncture, 
relaxation techniques, hypnotherapy, healing touch, 
movement therapy, pilates, rolfing structural integration, 
mindfulness, Ayurvedic medicine, traditional Chinese herbs 
and medicines, naturopathy, essential oils, aromatherapy, 
Reiki, cranial sacral therapy and applied prayer (as is 
common in all religions, like Christianity, Hinduism, 
Buddhism and Judaism) [22]. Biofield Energy Healing 
Treatment (The Trivedi Effect®) has been published in 
numerous peer-reviewed science journals due to its 
significant impacts in the science fields of biotechnology, 
genetics, cancer, microbiology, materials science, agriculture, 
and pharmaceuticals. These publications reported that 
Biofield Energy Treatment (The Trivedi Effect®) has the 
significant capability to transform the physical, structural, 
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chemical, thermal and behavioral properties of several 
pharmaceuticals [23, 24], nutraceuticals [25, 26], organic 
compounds [27-30], metals and ceramics in materials 
science [31-33], improve the overall productivity of crops 
[34, 35], as well as modulate the efficacy of various living 
cells [36-40]. Although magnesium gluconate displays the 
highest bioavailability and moderate solubility in water in 
comparison to other magnesium salts, humans still face 
problems in achieving their daily requirements of 
magnesium [41]. The physical and chemical properties such 
as particle size, crystalline structure, crystallite size, surface 
area, etc. of a pharmaceutical have a direct influence on the 
absorption, dissolution, and bioavailability of the drug [42]. 
The stability of a solid drug with respect to the atmospheric 
conditions is very important to the pharmaceutical industry 
during processing, formulation, storage, and packaging in 
order to achieve better therapeutic efficacy [43]. Biofield 
Energy Treatment (The Trivedi Effect®) has been reported 
to change the particle size, specific surface area, crystalline, 
chemical and thermal behavior of an atom/ion through 
possible mediation of neutrinos [44]. Scientific literature 
mentions that powder X-ray diffraction (PXRD), particle 
size distribution analysis (PSD), Fourier transform infrared 
(FT-IR) spectrometry, ultraviolet-visible (UV-vis) 
spectroscopy, thermogravimetric analysis (TGA), and 
differential scanning calorimetry (DSC) analysis play an 
vital role for solving various problems encountered in 
industries for the pharmaceutical/nutraceutical formulation 
and developments [45]. By considering these aspects, the 
physicochemical, structural, thermal and behavioral 
properties of the Biofield Energy Treated and untreated 
magnesium gluconate were studied using various analytical 
techniques including PXRD, PSD, FT-IR, UV-vis 
spectroscopy, TGA, and DSC. 
2. Materials and Methods 
2.1. Chemicals and Reagents 
Magnesium gluconate hydrate was procured from Tokyo 
Chemical Industry Co., Ltd. (TCI), Japan. All other chemicals 
used in the experiment were of analytical grade available in 
India. 
2.2. Energy of Consciousness Treatment Strategies 
Magnesium gluconate was one of the components of the 
new proprietary herbomineral formulation, which was 
developed by our research team and was used per se as the 
test compound for the current study. The test compound was 
divided into two parts, one part of the test compound did not 
receive any sort of treatment and was defined as the untreated 
or control magnesium gluconate sample. The second part of 
the test compound, which was denoted as The Trivedi Effect® 
Treated sample, was treated with The Trivedi Effect® - 
Energy of Consciousness Healing Treatment (Biofield Energy 
Healing Treatment) by the group of twenty renowned 
Biofield Energy Healers remotely. Eighteen Biofield Energy 
Healers were remotely located in the U. S. A. and two of 
which was remotely located in Canada, while the test 
compound was located in the research laboratory of GVK 
Biosciences Pvt. Ltd., Hyderabad, India. The Trivedi Effect® 
- Energy of Consciousness Healing Treatment was provided 
for 5 minutes through the Healer’s Unique Energy 
Transmission process remotely to the test compound, which 
was kept under laboratory conditions. None of the Biofield 
Energy Healers in this study visited the laboratory in person, 
nor had any contact with the compounds. Similarly, the 
control compound was subjected to “sham” healer for 5 
minutes, under the same laboratory conditions. The sham 
healer did not have any knowledge about The Trivedi Effect® 
Treatment. After that, the treated and untreated samples were 
kept in similar sealed conditions and characterized thoroughly 
by PXRD, PSD, FT-IR, UV-visible spectroscopy, TGA, and 
DSC analysis. 
2.3. Characterization 
2.3.1. Powder X-ray Diffraction (PXRD) Analysis 
The PXRD analysis was performed on PANalytical X’pert 
Pro powder X-ray diffractometer system. The X-ray of 
wavelength 1.54056 Å was used. The data was collected in the 
form of a chart of the Bragg angle (2θ) vs. intensity, and a 
detailed table containing information on peak intensity counts, 
d value (Å), relative intensity (%), full width half maximum 
(FWHM) (θ°). From the XRD results, the crystallite size (G) 
was calculated using X’pert data collector and X’pert high 
score plus processing software. The crystallite size (G) was 
calculated from the Scherrer equation [46, 47]. The method 
was based on the width of the diffraction patterns obtained in 
the X-ray reflected crystalline region. The crystallite size (G) 
was calculated by using the following Equation 1: 
G = kλ/ (bCosθ)                                       (1) 
Where, k is the equipment constant (0.5), λ is the X-ray 
wavelength (0.154 nm); b in radians is the full-width at half of 
the peaks and θ is the corresponding Bragg angle. 
Percent change in crystallite size (G) was calculated using 
the following equation 2: 
%	change	in	crystallite	size	 =
		
	
× 100       (2) 
Where GControl and GTreated are the crystallite size of the 
control and Biofield Energy Treated samples, respectively. 
A total of 500.18 mg of the control and treated samples 
individually were used for the analysis and prepared by the 
back loading technique using the sample preparation kit. 
The sample was spread on the holder ring in sufficient 
quantity to fill the ring cavity. It was then pressed down 
using a powder press block and scrapped the powder that 
was in surplus using a glass slide in order to get a densely 
packed specimen. The bottom plate was placed onto the 
holder ring and clamped in position. The sample holder was 
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then removed from the sample preparation table by turning 
it upside down. A smooth surface of the sample was 
obtained to ensure optimum results. 
2.3.2. Particle Size Distribution (PSD) Analysis 
The average particle size and particle size distribution 
were analyzed using Malvern Mastersizer 2000, UK, with a 
detection range from 0.01 µm to 3000 µm. The sample unit 
was filled with dispersant medium and operated the stirrer at 
2500 rpm. Alignment of the optics was done and taken the 
background measurement. After the background 
measurement, the sample was added in to the sample unit 
with constant monitoring of the obscuration. When the 
obscuration of the sample reached in between 15% and 20%, 
further addition of the sample stopped. When the 
obscuration was stable, the measurement was taken twice 
and the average was taken of the two measurements. The 
average histogram of the two measurements was recorded. 
Along with histogram, the data was presented in a table 
format which includes particle size (µm). Also, the values at 
below 10% level (d10), 50% level (d50), and 90% level (d90) 
were calculated from the histogram, and the calculations 
such as surface area (m2/g) were done by using Mastersizer 
2000 software. The percent change in particle size (d) for at 
below 10% level (d10), 50% level (d50), and 90% level (d90) 
was calculated using the following equation 3: 
%	change	in	particle	size =
##
#
× 100      (3) 
Where, dControl and dTreated are the particle size (µm) for at 
below 10% level (d10), 50% level (d50), and 90% level (d90) of 
the control and Biofield Energy Treated samples, respectively. 
The percent change in surface area (S) was calculated using 
the following equation 4: 
%	change	in	surface	area =
&	&	
&	
× 100			    (4) 
Where, SControl and STreated are the surface area of the control 
and Biofield Energy Treated samples, respectively. 
2.3.3. Fourier Transform Infrared (FT-IR) Spectroscopy 
FT-IR spectroscopy of the magnesium gluconate was 
performed using Spectrum Two (Perkin Elmer, USA) Fourier 
Transform Infrared Spectrometer with the frequency range of 
400-4000 cm-1 by using the pressed KBr disk technique. 
2.3.4. Ultraviolet-Visible Spectroscopy (UV-Vis) Analysis 
The UV-Vis spectral analysis was carried out using 
Shimadzu UV-2450 with UV Probe, Japan. The spectrum was 
recorded using 1 cm quartz cell with a slit width of 1.0 nm. The 
wavelength range chosen for recording the spectra was 190-
800 nm. The absorbance spectra (in the range of 0.2 to 0.9) and 
absorbance maximum (λmax) were recorded. 
2.3.5. Thermal Gravimetric Analysis (TGA) 
The TGA analysis was performed using TGA Q50 (TA 
Instruments, USA) at a heating rate of 10ºC/min from room 
temperature i.e. 25°C to 900°C in a nitrogen atmosphere. A 
total of 15 mg of sample was weighed in a platinum crucible. 
In TGA, the weight loss for each step was recorded in grams as 
well as in percent loss with respect to the initial weight. Also, 
the onset, endset, and peak temperature for each step were 
recorded in TGA. Percent change in weight loss (W) was 
calculated using the following equation 5: 
%	change	in	weight	loss =
)	)	
)	
× 100     (5) 
Where WControl and WTreated are the weight loss of the control 
and Biofield Energy Treated samples, respectively. 
2.3.6. Differential Scanning Calorimetry (DSC) 
Analysis was performed using the DSC Q20 (TA 
Instruments, USA) Differential Scanning Calorimeter. A total 
of 8.23 mg of sample was weighed and sealed in an aluminum 
pan and equilibrated at 25°C and heated up to 450°C at the 
heating rate of 10°C/min under nitrogen gas as purge 
atmosphere with the flow rate of 50 mL/min. The value for 
onset, endset, peak temperature, peak height (mJ or mW), peak 
area, and change in heat (J/g) for each peak were recorded. The 
percent change in melting point (T) was calculated using the 
following equation 6: 
%	change	in	melting	point =
++
+
× 100    (6) 
Where, TControl and TTreated are the melting point of the control 
and Biofield Energy Treated samples, respectively. 
The percent change in the latent heat of fusion (∆H) was 
calculated using the following equation 7: 
%	change	in	latent	heat	of	fusion =
∆-.-
.-
× 100		   (7) 
Where ∆HControl and ∆HTreated are the latent heat of fusion of 
the control and Biofield Energy Treated samples, respectively. 
3. Results and Discussion 
3.1. Powder X-ray Diffraction (PXRD) Analysis 
The PXRD diffractograms of both the control and The 
Trivedi Effect® treated magnesium gluconate, as shown in 
Figure 1, exhibited sharp and intense peaks indicating that both 
of the samples were crystalline in nature. PXRD data such as 
the Bragg angle (2θ), relative intensity (%), full width half 
maximum (FWHM) (θ°), and crystallite size (G) for the control 
and treated magnesium gluconate are presented in Table 1. The 
crystallite size was calculated using Scherrer equation [46, 47]. 
The highest intense peak in the both control and treated 
samples was observed at Bragg’s angle (2θ) equal to 5.06°. 
Table 1 displays the changes of the relative intensities and 
crystallite size of the treated magnesium gluconate compared 
with the control sample, while their Bragg’s angle (2θ) were 
almost similar.   
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Figure 1. Powder X-ray diffractograms of the control and Biofield Energy Treated magnesium gluconate. 
The crystallite sizes at position 2θ equal to nearly 5.06°, 
17.9°, 22.4°, 23.6°, 24.7°, 31.4°, 35.7°, 37.6°, and 40.4° (Table 
1, entry 1, 6, 11-13, 17, 20, 21, and 24) were significantly 
increased from 14.25% to 180.14% in the treated sample in 
comparison to the control sample. Consequently, the crystallite 
sizes of the treated sample at 2θ equal to nearly 9.88°, 13.9°, 
18.5°, 19.0°, 20.1°, 25.5°, 27.4°, 29.5°, 34.5°, 38.9°, 39.6°, 
41.7°, 44.1°, and 49.3° (Table 1, entry 2, 3, 7-9, 14-16, 22, 23, 
and 25-27) were significantly decreased from 12.48% to 
37.52% compared with the control sample. 
Table 1. PXRD data for the control and Biofield Energy Treated magnesium gluconate. 
Entry No. 
Bragg angle (°2θ) Relative Intensity (%) FWHM (°2θ) Crystallite size (G, nm) 
Control Treated Control Treated Control Treated Control Treated % change* 
1 5.06 5.06 100.00 100.00 0.0836 0.0669 52.70 65.85 24.96 
2 9.88 9.89 30.94 36.71 0.0836 0.1004 52.84 44.00 -16.73 
3 13.89 13.90 40.74 39.41 0.1004 0.1171 44.16 37.87 -14.26 
4 15.83 15.83 23.95 27.89 0.1171 0.1171 37.95 37.95 0.00 
5 16.38 16.41 14.00 15.01 0.1171 0.1171 37.98 37.98 0.00 
6 17.93 17.92 47.82 58.22 0.2342 0.0836 19.03 53.30 180.14 
7 18.48 18.48 69.97 80.43 0.1171 0.1506 38.08 29.61 -22.24 
8 19.00 19.01 54.43 65.74 0.1338 0.1673 33.35 26.68 -20.02 
9 20.09 20.10 45.40 21.36 0.1004 0.1171 44.52 38.17 -14.26 
10 20.93 20.92 25.28 31.12 0.1171 0.1171 38.23 38.22 0.00 
11 22.39 22.38 45.08 51.76 0.1840 0.1338 24.39 33.54 37.52 
12 23.63 23.63 45.56 51.18 0.1673 0.1338 26.88 33.61 25.04 
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Entry No. 
Bragg angle (°2θ) Relative Intensity (%) FWHM (°2θ) Crystallite size (G, nm) 
Control Treated Control Treated Control Treated Control Treated % change* 
13 24.72 24.73 20.71 23.12 0.1506 0.1004 29.92 44.88 50.00 
14 25.47 25.47 16.55 18.07 0.1171 0.1338 38.54 33.73 -12.48 
15 27.37 27.38 34.45 38.36 0.1673 0.2007 27.08 22.57 -16.64 
16 29.53 29.33 24.15 35.55 0.0836 0.1171 54.46 38.86 -28.64 
17 31.42 31.41 20.63 24.35 0.2007 0.0836 22.79 54.70 140.07 
18 31.86 31.86 18.53 20.54 0.1673 0.1673 27.36 27.36 0.00 
19 34.53 34.51 17.59 22.55 0.1338 0.1673 34.46 27.55 -20.03 
20 35.72 35.67 28.83 29.57 0.1338 0.1171 34.57 39.49 14.25 
21 37.62 37.64 21.29 24.42 0.1338 0.1171 34.76 39.72 14.27 
22 38.89 38.90 17.38 20.32 0.1338 0.1673 34.90 27.91 -20.02 
23 39.65 39.60 28.18 33.30 0.0836 0.1171 55.98 39.96 -28.62 
24 40.42 40.42 34.80 39.20 0.1338 0.1171 35.07 40.07 14.26 
25 41.72 41.75 17.49 20.59 0.1673 0.2676 28.16 17.61 -37.48 
26 44.14 44.14 24.57 26.50 0.0836 0.1338 56.83 35.51 -37.52 
27 49.27 49.28 12.64 14.29 0.2342 0.2676 20.69 18.10 -12.48 
Average crystallite size 36.51 36.47 -0.11 
FWHM: Full width half maximum, *denotes the percentage change in the crystallite size of Biofield Energy Treated sample with respect to the control sample. 
Furthermore, the crystallite sizes of the control and treated 
magnesium gluconate at 2θ equal to nearly 15.8°, 16.4°, 20.9°, 
and 31.9° (Table 1, entry 4, 5, 10, and 18) remained unchanged. 
The average particle size of The Trivedi Effect® treated sample 
was decreased by 0.11% as compared to the control sample. 
Scientific literature reported that the changes in the XRD 
patterns, such as crystallite size and relative intensities, 
indicated the modification of the morphology of the crystal as 
well as the proof of polymorphic transition [48-50]. As the 
crystal morphology of the treated sample was altered compared 
with the control sample, the treated sample might be a new 
polymorphic form of magnesium gluconate. The crystal 
pattern, size and even polymorphic form of a pharmaceutical 
play important roles in drug solubility, dissolution and 
bioavailability. It has been reported in the literature that the 
alteration in crystal morphology has significant impact on the 
in vitro dissolution rate, with potential for enhancing the 
bioavailability [43]. So, it can be concluded that The Trivedi 
Effect® Treatment might be a very useful method for enhancing 
the bioavailability of magnesium gluconate. 
3.2. Particle Size Distribution (PSD) Analysis 
The particle sizes at d10, d50, and d90 values and surface area 
of both the control and treated magnesium gluconate were 
investigated and the results are presented in Table 2 The 
control sample showed a particle size values of d10 (6.69), d50 
(38.07 µm), and d90 (161.29 µm). After the treatment, the 
particle size values of magnesium gluconate were found as 
5.93, 34.93, and 165.21 µm for d10, d50, and d90, respectively. 
Thus, the treatment lowered significantly the particle size at d10 
and d50 values of magnesium gluconate by 11.36% and 8.25%, 
respectively, whereas the particle size at d90 was increased by 
2.43% with respect to the control sample. 
Table 2. Particle size data (d10, d50, and d90) and surface area of the control and 
Biofield Energy Treated magnesium gluconate. 
Test Item d10 (µm) d50 (µm) d90 (µm) Surface area (m
2/g) 
Control 6.69 38.07 161.29 0.367 
Biofield 
Energy 
Treated 
5.93 34.93 165.21 0.402 
Percent 
change* (%) 
-11.36 -8.25 2.43 9.54 
*denotes the percentage change in the particle size data (d10, d50, and d90) and 
surface area of the Biofield Energy Treated sample with respect to the control 
sample. 
The surface area analysis revealed that the surface area of the 
treated magnesium gluconate (0.402 m2/g) was significantly 
increased by 9.54% from the surface area of the control 
magnesium gluconate (0.367 m2/g) as shown in Table 2. 
Poorly crystallized compounds possess more surface area 
and higher exchange capacities than well-crystallized 
compounds [51]. In addition, the variation of the crystal 
morphology in the Biofield Energy Treated sample, which was 
well-supported from PXRD data, may cause to alter the surface 
area of the treated magnesium gluconate in comparison with 
the control sample. It has been well established that the particle 
size, shape and surface area of pharmaceutical compounds have 
an important impact on solubility, dissolution and in vivo 
bioavailability, as well as in helping the design of new drug 
delivery systems [52, 53]. Reducing particle size and higher 
surface area would enhance the solubility of the solid particles, 
and consequently would increase the dissolution rate and 
bioavailability [54]. Thus, it is assumed that the treated 
magnesium gluconate might be dissolved and absorbed at a 
faster rate and may possibly have more bioavailability than 
normal magnesium gluconate. 
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3.3. Fourier Transform Infrared (FT-IR) Spectroscopy 
The FT-IR spectra of both the control and The Trivedi 
Effect® - Biofield Energy Treated magnesium gluconate, as 
shown in Figure 2, exhibited only one broad band with high 
intensity at 3398 and 3400 cm-1, respectively. This peak was 
attributed to the stretching vibrations of the hydroxyl groups 
originating from the water present in the magnesium gluconate. 
The bands of stretching vibrations of primary and secondary 
hydroxyl groups from the gluconate part of the compound 
appeared in this region. These bands were remained invisible 
due to the intensive broad band of water [55]. 
 
Figure 2. FT-IR spectra of the control and Biofield Energy Treated magnesium gluconate. 
The absorption peaks for the deformation vibration of the 
hydroxyl groups in the plane δ (OH) and out-of-plane γ (OH) 
that indicate the presence of primary and secondary hydroxyl 
groups were observed at 1434 cm-1, 636 cm-1, and 578 cm-1 in 
the spectrum of the control sample, whereas these peaks were 
found in the spectra of the treated magnesium gluconate at 
1434 cm-1, 636 cm-1, and 579 cm-1. The FT-IR spectra of both 
the control and treated samples displayed C-H stretching at 
2936 cm-1 and 1381 cm-1. A very sharp and intensive band at 
1606 cm-1 for C=O stretching vibration of a carbonyl group of 
carboxylate anion was observed in the spectrum of the control 
sample, while this vibration band was found in the spectrum of 
the treated magnesium gluconate at 1607 cm-1. The band of the 
C-O stretching vibrations of the primary alcohol group was 
observed at 1056 cm-1 in the spectra of both the control and 
treated samples. The absorption peaks at 1231 cm-1 and 1142 
cm-1 due to the C-O stretching vibrations of the secondary 
alcohol groups were observed in the spectrum in the control 
sample, while these absorption bands were observed in the 
treated magnesium gluconate at 1229 cm-1 and 1141 cm-1. 
The FT-IR analysis indicated that there was no significant 
alteration of the characteristic peaks for the functional groups. 
Hence, it can be concluded that the structure of the magnesium 
gluconate remained the same in both the treated and control 
samples. 
3.4. Ultraviolet-Visible Spectroscopy (UV-Vis) Analysis 
Literature reported that 0.1% aqueous solution of 
magnesium gluconate showed a maximum absorption peak 
(λmax) at 194.7 nm [56]. The UV-vis spectra of both the control 
and The Trivedi Effect® - Biofield Energy Treated samples 
(Figure 3) showed that the wavelength for the maximum 
absorbance (λmax) of both the control and Biofield Energy 
Treated samples were at 198.2 nm and 198.8 nm, respectively 
with a minor shift of absorbance maxima from 2.2717 (control 
sample) to 2.2812 (The Trivedi Effect® - Biofield Energy 
Treated sample). 
49 Mahendra Kumar Trivedi et al.:  An Impact of Energy of Consciousness (The Trivedi Effect®) on the   
Physicochemical, Thermal, Structural, and Behavioral Properties of Magnesium Gluconate 
 
 
Figure 3. UV-Vis spectra of the control and Biofield Energy Treated magnesium gluconate. 
The UV absorbance happens due to the different types of 
energy transitions from the singlet to the singlet excited state 
such as σ → σ∗, n → π∗, and π → π∗. These types of electronic 
transitions are occurred when the difference in energy between 
the lowest unoccupied molecular orbital (LUMO) and the 
highest occupied molecular orbital (HOMO) is significantly 
higher than the activation energy of the compound [57]. As 
there was no significant alternation in the λmax of the treated 
sample compared with the control, it is inferred that the 
structural configuration or activation energy of the treated 
sample was not different from the control sample. 
3.5. Thermal Gravimetric Analysis (TGA) 
The TGA and DSC are very useful techniques for the 
comparison of the thermal stabilities of pharmaceutical 
solids, determination of several kinetic parameters, and 
accomplishment of drug/excipient compatibility data for the 
pre-formulation study [58]. The TGA study of both the 
control and the treated magnesium gluconate (Figure 4) 
exhibited four thermal degradation steps and the data are 
presented in Table 3. 
Table 3. Thermal degradation steps of the control and Biofield Energy Treated magnesium gluconate. 
S. No. 
Temperature (°C) % Weight loss % Change* 
Control Treated Control Treated  
1st step of degradation 70.00 68.03 1.29 1.11 -13.95 
2nd step of degradation 193.59 186.13 9.53 8.51 -10.70 
3rd step of degradation 300.51 300.51 37.12 38.34 3.29 
4th step of degradation 595.86 595.77 23.31 21.64 -7.16 
Total weight loss - - 71.25 69.60 -2.32 
*denotes the percentage change in the weight loss of the Biofield Energy Treated sample with respect to the control sample. 
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The weight losses of the treated sample at the first, second, 
and fourth steps of thermal degradation were significantly 
decreased by 13.95%, 10.70% and 7.16%, respectively 
compared with the control sample. Consequently, the weight 
loss of the treated magnesium gluconate at the third step 
degradation was increased by 3.29% compared with the control 
sample. The first step degradation was probably associated 
with the removal of water of both the samples. 
 
Figure 4. TGA thermograms of both the control and Biofield Energy Treated magnesium gluconate. 
Overall, the total weight loss of the treated sample was decreased by 2.32% compared with the control sample. 
3.6. Differential Scanning Calorimetry (DSC) Analysis 
The DSC thermograms of both the control and treated magnesium gluconate (Figure 5) and showed two endothermic peaks. 
Their DSC data are presented in Table 4. The first broaden endothermic (minor) peak was due to the water removal from the 
sample. The second sharp endothermic (major) peak was due to the melting temperature of the magnesium gluconate. 
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Figure 5. DSC thermograms of the control and Biofield Energy Treated magnesium gluconate. 
The DSC data analysis (Table 4) revealed that the melting 
temperature of the treated sample (171.05ºC) was slightly 
(0.17%) decreased compared with the control sample 
(171.34ºC). The control and treated samples of magnesium 
gluconate exhibited a latent heat of fusion of 319.50 J/g and 
315.80 J/g, respectively. The result showed 1.16% decrease in 
the latent heat of fusion in the treated magnesium gluconate 
compared with the control sample (Table 4). 
Table 4. The latent heat of fusion (J/G) and melting point (°C) values of the control and Biofield Energy Treated magnesium gluconate. 
Endothermic peak Description Tonset (°C) Tpeak (°C) Tendset (°C) ∆Hfusion (J/g) 
 Control sample 63.98 83.21 95.67 20.87 
Minor peak Biofield treated sample 61.15 80.27 95.51 17.12 
 % Change* -4.42 -3.53 -0.17 -17.97 
 Control sample 157.77 171.34 200.00 319.50 
Major peak Biofield treated sample 156.18 171.05 200.00 315.80 
 % Change* -1.01 -0.17 0.00 -1.16 
Tonset:
 Onset melting temperature, Tpeak: Peak melting temperature, Tendset: Endset melting temperature, ∆H: Latent heat of fusion, 
adenotes the percentage change of 
Biofield Energy Treated sample with respect to the control sample. 
Additionally, ∆Hfusion for water removal from the treated sample was significantly decreased by 17.97% compared with 
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the control sample. The analysis indicated that the thermal 
stability of the treated sample was slightly lowered compared 
with the control sample. 
4. Conclusions 
The current analysis anticipated the significant impact of 
The Trivedi Effect® - Energy of Consciousness Healing 
Treatment (Biofield Energy Healing Treatment) on 
physicochemical, structural, thermal and behavioral properties 
of magnesium gluconate. The PXRD analysis showed that the 
crystallite size of The Trivedi Effect® Treated magnesium 
gluconate was significantly altered from -37.52% to 180.14% 
compared with the control sample. The average crystallite size 
was decreased in the treated sample by 0.11% compared with 
the control sample. Overall, the PXRD analysis indicated the 
change of the crystal morphology in the treated sample 
compared with the control sample. PSD analysis revealed that 
the particle sizes in the treated sample at d10 and d50 values 
were significantly decreased by 11.36% and 8.25%, 
respectively, while the particle size at d90 was increased in the 
treated sample by 2.43% with respect to the control sample 
compared with the control sample. The surface area analysis 
revealed that the surface area of the treated sample was 
significantly increased by 9.54% compared with the control 
sample. The TGA analysis revealed the four steps thermal 
degradation of the both samples and the total weight loss of the 
treated sample was decreased by 2.32% compared with the 
control sample. This finding revealed that the thermal stability 
of the treated sample was enhanced compared with the control 
sample. The DSC analysis demonstrated that the melting 
temperature of the treated sample (171.05ºC) was lowered by 
0.17% with a 1.16% decrease in the latent heat of fusion 
compared with the control sample (171.34ºC). Thus, The 
Trivedi Effect® treated magnesium gluconate would be a new 
polymorphic form of magnesium gluconate, which might have 
improved solubility, more bioavailability and long-term storage 
stability compared with the control sample. Briefly, The 
Trivedi Effect® - Energy of Consciousness Healing Treatment 
(Biofield Energy Healing Treatment) could be a useful approach 
in the design of better nutraceutical and/or pharmaceutical 
formulations that can offer significant therapeutic responses 
against various diseases such as diabetes mellitus, allergies and 
septic shock; stress-related disorders like sleep disorder, 
insomnia, anxiety, depression, Attention Deficit Disorder 
(ADD), Attention Deficit Hyperactive Disorder (ADHD), mental 
restlessness (mind chattering), brain frog, low libido, impotency, 
lack of motivation, mood swings, fear of the future, confusion, 
migraines, headaches, forgetfulness, overwhelm, loneliness, 
worthlessness, indecisiveness, frustration, irritability, chronic 
fatigue, obsessive/compulsive behavior and panic attacks; 
inflammatory diseases and immunological disorders like Lupus, 
Systemic Lupus Erythematosus, Hashimoto Thyroiditis, Type 1 
Diabetes, Asthma, Chronic peptic ulcers, Tuberculosis, Hepatitis, 
Chronic active hepatitis, Celiac Disease (gluten-sensitive 
enteropathy), Addison Disease, Crohn's disease, Graves’ 
Disease, Pernicious and Aplastic Anemia, Sjogren Syndrome, 
Irritable Bowel Syndrome (IBS), Multiple Sclerosis, Rheumatoid 
arthritis, Chronic periodontitis, Ulcerative colitis, Chronic 
sinusitis, Myasthenia Gravis, Atherosclerosis, Vasculitis, 
Dermatitis, Diverticulitis, Rheumatoid Arthritis, Reactive 
Arthritis, Alopecia Areata, Psoriasis, Scleroderma, Fibromyalgia, 
Chronic Fatigue Syndrome and Vitiligo; aging-related diseases 
like cardiovascular disease, arthritis, cancer, Alzheimer’s 
disease, dementia, cataracts, osteoporosis, diabetes, 
hypertension, glaucoma, hearing loss, Parkinson’s Disease, 
Huntington’s Disease, Prion Disease, Motor Neurone Disease, 
Spinocerebellar Ataxia, Spinal muscular atrophy, Amyotrophic 
lateral sclerosis, Friedreich’s Ataxia and Lewy Body Disease; 
chronic infections and much more. 
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